Industry Overview

North America artificial tear market was valued at $638.8 million in 2025 and is projected to reach $1,021.7 million by 2035, growing at a CAGR of 4.9% during the forecast period (2026–2035). The North America artificial tear market is growing consistently as dry eye syndrome becomes increasingly prevalent across diverse patient groups, including aging populations, digital screen users, and individuals exposed to environmental stressors. Demand is rising as clinicians emphasize early and continuous ocular surface management to prevent progression to chronic dry eye disease. Growth is further supported by expanding awareness of self-care ophthalmic solutions, wider OTC product availability, and strong recommendations for lubricating eye drops as first-line therapy in dry eye treatment guidelines across the region. Market expansion is also being accelerated by innovation in formulations—particularly preservative-free, lipid-enhanced, and nano-emulsion artificial tears designed to improve tear film stability, reduce inflammation, and extend ocular surface retention time.

Market Dynamics

Growing Emphasis on Ocular Surface Health and Dry Eye Management

The North America artificial tear market is expanding steadily as ophthalmologists, optometrists, and primary care providers place a stronger focus on early intervention and continuous management of dry eye disease. Rising prevalence of meibomian gland dysfunction (MGD), age-related tear film instability, post-operative dryness, and digital-screen–induced dry eye is driving widespread adoption of artificial tears across the region. Elevated exposure to air conditioning, pollution, and extended contact lens wear further contributes to escalating incidence rates. Clinical guidelines in the U.S. and Canada increasingly emphasize the use of lubricating eye drops as first-line therapy, reinforcing their role in both acute symptom relief and long-term disease management. As healthcare providers prioritize patient comfort, vision quality, and prevention of chronic ocular surface disorders, demand for effective, multi-action artificial tear formulations continues to strengthen across North America.

Innovation in Formulations and Rapid Advancement of Premium Eye-Lubrication Technologies

Technological innovation is a major growth catalyst in the North American artificial tear market. Manufacturers are rapidly introducing next-generation formulations such as preservative-free, lipid-enhanced, gel-based, and nano-emulsion tears designed to mimic natural tear film composition and deliver longer-lasting relief. Advancements in osmoprotective ingredients, hydration-retention agents, and anti-inflammatory components are improving therapeutic outcomes for patients with moderate to severe dry eye disease. Additionally, the rise of unit-dose vials, multi-dose preservative-free systems, and contact-lens-compatible formulations supports safer, more convenient use across varied settings. Strong presence of leading ophthalmic companies, combined with increasing adoption of personalized ocular-surface treatment plans, is accelerating the shift toward premium and specialty artificial tears. As digital lifestyles intensify and patients seek high-performance OTC and prescription-based solutions, advanced eye-lubrication technologies are becoming integral to modern eye-care practices throughout the United States and Canada.

Market Segmentation

• Based on type, the market is segmented into glycerin-derived tears, cellulose-derived tears, oil-based / emulsion-based tears, polyethylene glycol (PEG)-based tears, propylene glycol-based tears, and hyaluronic acid.
• Based on the delivery mode, the market is segmented into eye drops and ointments.
• Based on the application, the market is segmented into dry eye syndrome, digital eye strain, and contact lens discomfort/moisture retention.
• Based on the end user, the market is segmented into retail pharmacies (OTC), online pharmacies, hospitals & ophthalmic clinics, and others.

Preservative-Free Drops Segment to Lead the Market with the Largest Share

In the North America artificial tear market, the preservative-free drops segment holds the largest and most influential share within the type category. This dominance is driven by the region’s strong clinical preference for safer, irritation-free formulations—especially for patients requiring frequent or long-term dry eye management. Concerns over preservative-related ocular surface damage, particularly from benzalkonium chloride (BAK), have accelerated the transition toward preservative-free options across the United States and Canada. Dry Eye Disease continues to rise sharply in North America due to aging populations, intensive digital screen exposure, widespread contact lens use, and increasing rates of refractive and cataract surgeries. These factors significantly reinforce demand for preservative-free artificial tears, which are now widely recommended by ophthalmologists and optometrists to minimize inflammation and support healthier tear film restoration.

Eye Drops: Key Segment Driving Market Growth Across North America

Among all product formats in the North America artificial tear market, eye drops continue to represent the most dominant and fastest expanding delivery mode, serving as the central driver of regional market growth. Their convenience, rapid symptom relief, and strong consumer familiarity make eye drops the preferred first-line choice for managing mild to moderate dry eye symptoms. In North America, rising digital eye strain, air-conditioned indoor environments, extensive device use, environmental pollutants, and high rates of contact lens wear have significantly increased day-to-day reliance on eye drops as a quick, non-invasive hydration therapy. Eye-care professionals consistently recommend drops due to their ease of self-administration, broad OTC availability, and suitability for multiple daily applications, all of which support high repeat usage and strong annual demand. As a result, eye drops remain the cornerstone of dry eye management and continue to play a defining role in shaping the growth trajectory of the North American artificial tear market.

Regional Outlook

North America artificial tear market is further divided by countries, including US and Canada.

US Dominates the Market with Major Share

The US holds a dominant share of the North America artificial tear market, supported by its highly developed eye-care ecosystem and strong consumer demand for advanced dry eye management solutions. The country’s large population of chronic dry eye patients, driven by intensive digital device usage, widespread screen-based work culture, aging demographics, and environmental triggers, continues to accelerate the adoption of artificial tear products across all age groups. The US also benefits from a robust ophthalmology and optometry infrastructure, where clinicians actively promote early intervention and long-term ocular surface maintenance. Growing awareness of preservative-free, lipid-based, and premium tear formulations has further fueled market penetration, with consumers demonstrating a strong preference for high-performance OTC products.

Market Players Outlook

The major companies operating in the North America artificial tear market include AbbVie Inc., Alcon Inc., Bausch Health Companies Inc., Rohto Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In March 2025, Bausch + Lomb launched a new line of preservative-free artificial tears in the United States, featuring enhanced lipid-based formulations designed for patients with moderate to severe dry eye, reinforcing the company’s leadership in advanced ocular-surface care.
• In February 2025, Alcon expanded its North American product portfolio by introducing multi-dose preservative-free eye drops optimized for contact-lens users and post-surgical patients, signaling a growing emphasis on patient convenience and long-term ocular health.
• In January 2025, Hubble Contacts partnered with leading pharmacy chains across the U.S. to enhance the distribution of its over-the-counter artificial tear solutions, increasing accessibility for digital-device users and consumers with mild to moderate dry eye symptoms.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the North America artificial tear Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.